Sermorelin

Grade C: Preliminary or limited human evidence

TL;DR: Sermorelin is a synthetic 29-amino-acid fragment of growth hormone-releasing hormone (GHRH) with a prior FDA approval history as Geref, which the manufacturer voluntarily discontinued around 2008 (FDA approval withdrawn 2009) for commercial, not safety or efficacy, reasons. Human evidence from its approved-era use supports its ability to stimulate pituitary GH secretion, and it was studied in children with growth hormone deficiency; adult long-term efficacy data are limited to small or uncontrolled studies. Its current use as a compounded medication for adult GH optimization is off-label and not supported by randomized controlled trials in that population.

Key Takeaways

Grade C: Preliminary or limited human evidence
Not FDA approved: No currently marketed FDA-approved product (Geref withdrawn 2009 for commercial reasons); available via 503A compounding (Category 1).
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sermorelin chemical structure — Structure via PubChem CID 16132413

Mechanism

Sermorelin binds GHRH receptors on anterior pituitary somatotroph cells, stimulating pulsatile secretion of endogenous growth hormone.

Evidence

Sermorelin is a synthetic 29-amino-acid fragment of growth hormone-releasing hormone (GHRH) with a prior FDA approval history as Geref, which the manufacturer voluntarily discontinued around 2008 (FDA approval withdrawn 2009) for commercial, not safety or efficacy, reasons. Human evidence from its approved-era use supports its ability to stimulate pituitary GH secretion, and it was studied in children with growth hormone deficiency; adult long-term efficacy data are limited to small or uncontrolled studies. Its current use as a compounded medication for adult GH optimization is off-label and not supported by randomized controlled trials in that population.

Safety and risks

The evidence base for compounded sermorelin reflects a grade C compound: there are human data from the Geref approval era, but no contemporary RCTs for off-label adult use. Known adverse effects include injection-site reactions, flushing, headache, dizziness, nausea, and transient joint pain. Persistent GH stimulation carries theoretical risks of glucose dysregulation, as growth hormone is counter-regulatory to insulin; prolonged use without monitoring is not advisable. Antibody formation to sermorelin has been documented, potentially blunting response over time. Compounded formulations are not subject to FDA manufacturing oversight for potency or sterility. Any preclinical GHRH findings in disease models (such as neurodegeneration) should not be interpreted as human evidence for those uses.

Interactions

Glucocorticoids may blunt the GH response to sermorelin; hypothyroidism can impair GH secretion and should be corrected before or during therapy; concurrent GH administration would be redundant.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

Sermorelin is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).